Search research articles
Contact Us
Filters
Showing results (91-100 of 137) with videos related to
Page
of 14
Sort By:
Annals of Hematology
|
August 18, 2016
Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes
Yoo Jin Lee, Sung Woo Park, In Hee Lee, et al.
American Journal of Hematology
|
January 11, 2020
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)
Ho Sup Lee, Kihyun Kim, Seok Jin Kim, et al.
Annals of Hematology
|
August 4, 2018
Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts
Dong Won Baek, Yoo Jin Lee, Hyunjeong Kim, et al.
American Journal of Clinical Oncology
|
December 6, 2012
Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma
Ho Sup Lee, Lee Chun Park, Eun Mi Lee, et al.
Cancer Research and Treatment
|
December 30, 2014
Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
Junshik Hong, Seok Jin Kim, Jae-Sook Ahn, et al.
Haematologica
|
August 18, 2025
Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party (KMMWP-174 study)
Jung Yeon Lee, Seungpil Jung, Suein Choi, et al.
Nature Communications
|
March 30, 2024
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
Changhee Park, Ho Sup Lee, Ka-Won Kang, et al.
Scientific Reports
|
January 1, 2020
Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
Jung Yong Hong, Dok Hyun Yoon, Sang Eun Yoon, et al.
Hemasphere
|
March 4, 2024
Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
Hyungwoo Cho, Kihyun Kim, Sang Eun Yoon, et al.
Blood Research
|
October 19, 2017
Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial
Jeongkuk Seo, Won Seog Kim, Jin Seok Kim, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 137) with videos related to
Sort By:
Page
of 14
Annals of Hematology
|
August 18, 2016
Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes
Yoo Jin Lee, Sung Woo Park, In Hee Lee, et al.
American Journal of Hematology
|
January 11, 2020
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)
Ho Sup Lee, Kihyun Kim, Seok Jin Kim, et al.
Annals of Hematology
|
August 4, 2018
Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts
Dong Won Baek, Yoo Jin Lee, Hyunjeong Kim, et al.
American Journal of Clinical Oncology
|
December 6, 2012
Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma
Ho Sup Lee, Lee Chun Park, Eun Mi Lee, et al.
Cancer Research and Treatment
|
December 30, 2014
Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
Junshik Hong, Seok Jin Kim, Jae-Sook Ahn, et al.
Haematologica
|
August 18, 2025
Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party (KMMWP-174 study)
Jung Yeon Lee, Seungpil Jung, Suein Choi, et al.
Nature Communications
|
March 30, 2024
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
Changhee Park, Ho Sup Lee, Ka-Won Kang, et al.
Scientific Reports
|
January 1, 2020
Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
Jung Yong Hong, Dok Hyun Yoon, Sang Eun Yoon, et al.
Hemasphere
|
March 4, 2024
Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
Hyungwoo Cho, Kihyun Kim, Sang Eun Yoon, et al.
Blood Research
|
October 19, 2017
Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial
Jeongkuk Seo, Won Seog Kim, Jin Seok Kim, et al.
Page
of 14